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OBJECTIVE — Paraoxonase (PON) exhibits esterase activity (PON-AREase) and lactonase
activity (PON-HCTLase), which prevent LDL oxidation and detoxify homocysteine thiolactone
(HCTL).TheroleofHCTLandPON-HCTLaseasariskfactorforthemicrovascularcomplication
in diabetic retinopathy at the level of vitreous has not been investigated.
RESEARCH DESIGN AND METHODS — Undiluted vitreous from patients with pro-
liferative diabetic retinopathy (PDR) (n  13) and macular hole (MH) (n  8) was used to
determine PON-HCTLase and PON-AREase activity spectrophotometrically. HCTL levels were
detected by liquid chromatography–tandem mass spectrometry. In vitro studies were done in
primary cultures of bovine retinal capillary endothelial cells (BRECs) to determine the dose- and
time-dependent effect of HCTL and homocysteine (Hcys) on PON-HCTLase activity, as well as
to determine mRNA expression of PON by RT-PCR.
RESULTS — AsigniﬁcantincreaseinHCTLandPON-HCTLaseactivitywasobservedinPDR
comparedwithMH(P0.036,P0.001),withasigniﬁcantpositivecorrelationbetweenthem
(r0.77,P0.03).TheinvitrostudiesonBRECsshowedadose-andtime-dependentincrease
inthePON-HCTLaseactivityandmRNAexpressionofPON2whenexposedtoHCTLandHcys.
CONCLUSIONS — This is the ﬁrst study showing elevated levels of vitreous HCTL and
PON-HCTLase activity in PDR. These elevations are probably a protective effect to eliminate
HCTL, which mediates endothelial cell dysfunction. Thus, vitreous levels of HCTL and PON
activity can be markers of diabetic retinopathy. The bioinformatics analysis reveals that the
structure and function of PON that can be modulated by hyperhomocysteinemia in PDR can
affect the dual-enzyme activity of PON.
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H
yperhomocysteinemia is a well-
established independent risk factor
for the development of macrovas-
cular and microvascular diseases (1). Re-
cent reports show that increased
homocysteine thiolactone (HCTL) levels
are associated with diabetic macrovascu-
lopathy (2). HCTL is formed in all cell
types as a result of error-editing met-
tRNA synthetase when there is excess ho-
mocysteine (Hcys). The interaction of
HCTL with proteins leads to protein ho-
mocysteinylation and loss of function (3).
Therefore, detoxiﬁcation of HCTL is cru-
cial. This is possible by the lactonase
(HCTLase)activityofparaoxonase(PON)
(4). The enzyme PON is a calcium-
dependent 45-kDa protein coded by
chromosome 7q21-22. The PON gene
family in humans has three members:
PON1, PON2, and PON3. Whereas
PON1 and PON3 are associated with
serumHDL(5),PON2isubiquitouslyex-
pressed in tissues (6). PON1 exhibits an-
tioxidant properties, thereby preventing
the accumulation of oxidized LDL, and
PON2 acts mainly at the cellular level (7).
Lipid oxidation plays a role not only in
macrovascular diseases but also in micro-
vascular dysfunction, and serum PON1
activity was decreased in patients with di-
abetic retinopathy (8). While elevated
Hcys in the vitreous of patients with pro-
liferative diabetic retinopathy (PDR) was
reported by us and others (9,10), there
are no reports on HCTL levels and PON
activity. This study aims to detect the vit-
reous levels of HCTL, PON-HCTLase,
and esterase (PON-AREase) activity in
PDR case subjects and in in vitro studies
in bovine retinal capillary endothelial
cells (BRECs).
RESEARCH DESIGN AND
METHODS— Allexperimentsinvolv-
ing human subjects adhered to the tenets
of the Declaration of Helsinki. In patients
with PDR, the clinical ocular ﬁndings
were graded at the time of vitrectomy for
the presence of hemorrhage, tractional
retinal detachment, and presence or ab-
senceofpatentnewvesselsintheretinaor
optic disc. Macular hole (MH) patients
with an idiopathic full-thickness retinal
defect of more than 400 m with pos-
terior vitreous detachment were in-
cluded as disease control subjects.
Clinical details of the patients with PDR
and MH are given in Tables I and II in
the online appendix, available at http://
care.diabetesjournals.org/cgi/content/
full/dc10-0132/DC1. Undiluted vitreous
samplesfrom13patientswithPDR(mean
age 52  7 years; 7 male and 6 female)
and 8 patients with MH (mean age 56 
10 years; 5 male and 3 female) were col-
lected during vitreoretinal surgery, cen-
trifuged, and frozen at 80°C. Vitreous
HCTLlevels,PON-AREaseactivity,PON-
HCTLase activity, total protein, thiobar-
bituric acid reacting substances (TBARS),
total antioxidant capacity (TAC), and to-
tal thiols were measured.
In vitro experiments in BRECs
BRECs were cultured and characterized
as endothelial cells using factor VIII
and vascular-endothelial cadherin (VE-
cadherin). The cells were exposed to
various concentrations (25, 50, 100,
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at different time points (3, 6, 12, 24,
and 48 h) in Dulbecco’s modiﬁed Ea-
gle’s medium: nutrient mixture F-12
(DMEM/F12). The activity of PON-
HCTLase and PON-AREase were esti-
mated in the cell lysates.
DL-homocysteineandhomocysteine-
thiolactone-HCl were obtained from
Sigma, and L-homatropine was from
Boehringer Ingelheim, Germany. Mer-
captoethanol(MSgrade),acetonitrile(MS
grade), formic acid (MS grade), phenyl-
acetate (PA), -thiobutyrolactone (-
TBL), 5,5-dithiobis(2-nitrobenzoic acid)
(DTNB), thiobarbituric acid (TBA), iron
(Fe), EDTA, benzoic acid, trichloroacetic
acid, acetic acid, and dimethyl sulfoxide
(DMSO) were obtained from Sigma.
Other materials used were DMEM/F12
(GIBCO), endopan media (Genex), FBS
(GIBCO), factor VIII antibody (Dako),
VE-cadherin (Chemicon), GenElute
mammalian total RNA miniprep kit
(Sigma), and cDNA conversion (Thermo-
Script; Invitrogen).
Cytotoxic effect of HCTL and Hcys
in BRECs
BRECs were grown in a 96-well plate
(1,000 cells per well) and exposed to
varying concentrations of Hcys (25, 50,
100, and 200 mol/l) for 3, 6, 12, 24,
and 48 h, respectively, in DMEM/F12.
The formazan, formed after treatment
with MTT, was dissolved in DMSO and
read at 570 nm to assess the cell
viability.
HCTL estimated using liquid
chromatography–tandem mass
spectrometry (LC-MS/MS)
The liquid chromatography separation of
HCTL in the vitreous was done by gradi-
ent elution using acetonitrile with 0.1%
formic acid and water with 0.1% formic
acid in a 70:30 ratio, pumped at a ﬂow
rate of 0.5 ml/min in a Thermo Surveyor
quaternary HPLC pump (Thermo Elec-
tron, Waltham, MA) coupled with a 4000
Q Trap (Applied Biosystems, Foster City,
CA)andpositiveelectronsprayionization
(ESI)mode.Theanalyticalseparationwas
achievedbyusingChromolithSpeedROD
RP-18e (50  4.6 mm) (Merck, Darm-
stadt, Germany) within the run time of 5
min, with homatropine was the internal
standard. Analyst software version 1.4.2
was used to control all the parameters of
mass spectrometry. Quantiﬁcation was
performed using the multiple reaction
monitoring (MRM) mode, on the basis of
parent 3 product ion transitions for
HCTL (118.2 3 56) and homatropine
(276.1 3 142). Source-dependent pa-
rameters optimized were gas 1 (40 psi),
gas 2 (40 psi), curtain gas (10 psi), ion
spray voltage (5,500 V), and temperature
(300°C). Compound-dependent parame-
ters, declustering potential, entrance po-
tential, collision energy and cell exit
potential, and dwell time were set at 75,
10, 35, 10, and 200 for both analyte and
theinternalstandard.Then20lofeither
standard or sample was mixed with 200
l of extraction solvent (70:30 ratio of
acetonitrile to water with 1% zinc sulfate)
containing homatropine at a concentra-
tion of 250 ng as the internal standard
(11,12).
Determination of PON-AREase
activity
PON-AREase activity was measured us-
ing the method of Cabana et al. (13).
The rate of hydrolysis of substrate PA
was measured spectrophotometrically
in the kinetic mode by detecting the in-
crease in phenol concentration at 270
nm. Undiluted vitreous was added to
the buffer, consisting of 10 mmol/l Tris
and 1 mmol/l CaCl2, pH 8.0. Enzyme
activity was expressed as micromoles
PAhydrolyzedpermilliliterperminute.
Determination of PON-HCTLase
activity
ThePON-HCTLase–activityassaywasstan-
dardizedinhouseusing-TBLassubstrate,
and the rate of hydrolysis was measured
spectrophotometrically in the kinetic mode
at 450 nm (main wavelength) and 546 nm
(subwavelength), suitably modifying the
method of Koubaa et al. (14). Then 5 lo f
vitreous sample was used for the assay with
DTNB as chromogen at pH 7.2, using 100
mmol/l of phosphate buffer. Enzyme activ-
ity was expressed in U/l.
Activity stain for PON using PA as
substrate
The AREase activity of PON protein in the
vitreous was observed by doing an activity
stain using PA as substrate. The liberated
phenol couples with the hexazotized
pararosanilinesolutiontogiveaninsoluble,
brightlycoloredazodyeseenaspinkbands
inthegel.Brieﬂy,50gofthevitreouspro-
tein from patients with either MH or PDR
wasrunonanativepage(12%).Thegelwas
then immersed in a staining solution
(pararosaniline 0.125 mol/l, sodium nitrite
4%, phenylacetate 1 mmol/l in phosphate
buffer pH 6.8–7.2.) for1ha t37°C. Once
the bands were visualized, the gel was
destained with 0.33% sodium meta-
bisulphate in phosphate buffer (15).
Determination of TBARS
Estimation of vitreous TBARS was done
spectrophotometrically on the basis of ab-
sorbance of the chromophore at 530 nm.
Theresultswereexpressedasnanomolesof
malondialdehyde released per milliliter per
milligram of protein (16).
Determination of TAC
Estimation of vitreous TAC was done
spectrophotometrically by a Fenton-
type reaction. Antioxidants from the
added sample of human ﬂuid suppress
Table 1—Homocysteine thiolactonase, arylesterase activity, and oxidative stress parameters in the vitreous of PDR compared with MH case
subjects
MH PDR P
n 81 3
Homocysteine thiolactonase (U/l) 78.5  12.7 175.1  16.4 0.000
Arylesterase activity (mol/ml/min) 13.8  1.6 1.5  1.7 0.000
TBARS (nmol/ml/mg protein) 24.42  5.2, 26.05 (2.7) 17.1  15.2, 11.6 (22.3) 0.090
TAC (mmol) 0.22  0.03 0.319  0.24 0.0001
Total thiols (mmol) 43.88  6.3 28.7  12.9 0.000
Protein (mg/ml) 1.29  0.2 2.83  2.5 0.002
Data are means  SD and median (interquartile range).
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sured at 532 nm (17).
Determination of total thiols
Estimation of total thiols (a disulphide
compound that is readily reduced) was
measured spectrophotometrically using
DTNB as a chromogen at 412 nm (18).
Statistical analysis
Student t test was used to compare the
continuous variables between groups.
Pearson correlation was used to calcu-
late the r value. Statistical signiﬁcance
was deﬁned as P  0.05. The statistical
analysis was done using SPSS version
14.0.
RESULTS
PON-HCTLase and PON-AREase
activity in vitreous
The PON-HCTLase activity in the vitre-
ous of PDR case subjects was found to be
signiﬁcantly elevated (mean 175.17 
16.4 units/l) compared with athat of MH
Figure 1—PON activity and HCTL levels in the vitreous of PDR and MH case subjects. Distribution graphs show the reciprocal relationship
of HCTLase and AREase in PDR (n  13) and MH (n  8). A: PON-AREase activity. B: PON-HCTLase activity. C: Activity staining for PON
proteininthevitreoususingphenylacetateassubstrateandparasoanilineaschromogen.Thebandwasobservedat66kDa(lane1:MH;lanes
2–4: PDR; lane 5: high–molecular weight marker). Representative liquid chromatography–tandem mass spectrometry chromatogram show-
ing the HCTL (left) and the corresponding internal standard, namely homatropine (right). D: Standard vitreous. E: MH vitreous. F: PDR
vitreous. The m/z of HCTL is 118.2 and homatroprine is 276.1 (seen as the peak). G: Distribution of HCTL levels in PDR (n  9) and MH
(n  3) case subjects. Correlation between HCTL and PON-HCTLase is shown. H: PDR (n  9),  ;M H( n  3), F. (A high-quality color
representation of this ﬁgure is available in the online issue.)
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0.00). Correspondingly, a signiﬁcant de-
crease in PON-AREase activity was ob-
served in PDR (1.5  1.7 mol/ml/min)
compared with MH (3.8  1.6 mol/ml/
min) (P  0.00) (Table 1). Distribution of
PON-AREase and PON-HCTLase activity
shows a shift in the median, with a 9-fold
dropinthePON-AREaseactivityanda2.2-
fold increase in PON-HCTLase in PDR
compared with MH case subjects (Fig. 1A
and B). There were six case subjects with
Figure 1—Continued.
Figure 2—In vitro experiments. PON-HCTLase activity in BRECs exposed to Hcys and HCTL. Graphs showing the dose- and time-dependent increase in
PON-HCTLaseactivityaftertreatmentwithHCTL(A)orHcys(B).C:PON-AREaseandPON-HCTLaseactivityinBRECsexposedtoHcysandHCTLat
200mol/lcomparedwiththebaselinecontrolactivity.D:mRNAexpressionofPON2inBRECsexposedtoHcysandHCTL(200mol/lat24h).ThePCR
was carried out using the following primers for bovine glyceraldehyde 3-phosphate dehydrogenase (GAPDH): forward primer 5-
TGTTCCAGTATGATTCCACCC-3and reverse primer 5-GTCTTCTGGGTGGCAGTGAT-3corresponding to 424 bp, and for PON2: forward primer
5-CCT TCC TAA TTG CCA CCT GA-3and reverse primer 5-TGG AGG CCT GGA CAT TTT AG-3, corresponding to 	150 bp. The bands obtained
were quantiﬁed using National Institutes of Health ImageJ software after normalization to GAPDH. (A high-quality color representation of this ﬁgurei s
available in the online issue.)
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and there was no signiﬁcant difference in
the activity of PON-HCTLase and PON-
AREase in this group. Activity staining for
PON-AREaserevealedthepresenceofPON
protein in the vitreous (Fig. 1C). To see if
thisincreaseinPON-HCTLaseisassociated
with an increase in HCTL levels, PON-
HCTLase levels were detected in the vitre-
ous by mass spectrometry (Fig. 1D–F).
There was a signiﬁcant increase in HCTL
levels in the vitreous of PDR case sub-
jects (1.37  0.51 nmol/l) compared
with MH case subjects (0.65  0.18
nmol/l) (Fig. 1G).
Correlation between PON-HCTLase
and PON-AREase with HCTL
A signiﬁcant positive correlation was ob-
served between vitreous HCTL levels and
PON-HCTLase activity in PDR and MH
(n  3) (r  0.88; P  0.03) (Fig. 1H).
However,nosigniﬁcantcorrelationwasob-
served with PON-AREase and HCTL.
Oxidative stress parameters in the
vitreous
There was a signiﬁcant decrease in total
thiols in PDR compared with MH case
subjects (P  0.00), with signiﬁcant in-
crease in the TAC levels (P  0.0001).
This increase in TAC value in spite of
reduced thiol status can be attributed to
the cumulative effect of small molecule
antioxidants, such as vitamins E and C.
Izuta et al. (19) suggest that the thiore-
doxin and Nrf2/ARE pathways can also
mediate the redox status in the vitreous
body of PDR cases and have reported
increased antioxidant potential in the
vitreous of PDR cases. However, the al-
terationintheTBARSlevelswasnotsig-
niﬁcant,andthemedianshowed11.6in
PDR (interquartile [IQ] range 22.3) and
26.05 in MH (IQ range 2.7). The total
protein level was found to be signiﬁ-
cantly elevated in PDR (P  0.002) (Ta-
ble 1).
In vitro studies on BRECs
The MTT assay revealed that the cells
were viable at all the concentrations of
HCTL and Hcys tested until 48 h. The in
vitro experiments showed a dose- and
time-dependent increase in PON-
HCTLase activity when exposed to both
HCTL and Hcys (Fig. 2A and B). PON-
HCTLase activity was found to be signiﬁ-
cantly increased and maximal at 200
mol/l at 24 h for both HCTL and Hcys
exposure compared with untreated con-
trol (P  0.000). Correspondingly, the
PON-AREase activity was signiﬁcantly
decreased (P  0.000) (Fig. 2C). In the
same experimental condition, the mRNA
expression of PON enzyme was tested
and found to be increased for both HCTL
and Hcys, and the effect was very pro-
nounced in Hcys (Fig. 2D).
CONCLUSIONS — Homocysteiny-
lated protein mediates the development
and progression of both diabetic macro-
Figure3—BioinformaticanalysisofPON2interactionwithHcys.A:ResiduesofthePON2proteinthathavehydrogenbondingwiththeligandHcys.
B: Residues of the PON2 protein that have hydrophobic interaction with the ligand Hcys.
Table 2—Binding kinetics of the substrates HCTL and PA and the ligand Hcys with PON2 protein
Ligands
Binding energy
(kcal/mol)
Residues involved in hydrogen
bonding
Residues involved in hydrophobic
interactions
Inhibitory
constant (Ki)
Hcys 5.08 Asp168, Ile169, Ile225, Thr170, Ile55 Ile116, Leu270, Asn226, Asp56, Ca355 188.88 mol/l
HCTL 6.63 Asp168, Ile169, Ile225, Thr170 Ser117, Ile116, Asn226, Leu270, Ca355 13.87 mol/l
PA 4.73 Thr118, Ala171 Ser117, Ile225, Ile116, Ile169, Leu270,
Thr170, Asn226, Ca355
338.45 mol/l
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cations (20,21). However, its impact on
the microvascular endothelial cell is still
not well understood. Increased levels of
Hcys have been reported to increase the
concentration of HCTL levels (3). Serum
PON-HCTLase and PON-AREase activity
of PON were reported to be signiﬁcantly
lowered in diabetic patients (8). In this
study, we observed for the ﬁrst time that
the vitreous HCTL and PON-HCTLase
activity is signiﬁcantly increased in the
vitreous of PDR case subjects compared
with MH case subjects. The increase of
PON in vitreous could be contributed to
by the inner retinal barrier permeability
and proliferating endothelial cells, which
are characteristic of PDR. PON2, which is
ubiquitouslypresentinalltissues,hasthe
highestlactonaseactivity,thoughallthree
isoforms exhibit it (6). The in vitro study
supports this fact, wherein exposure of
Hcys and HCTL increases the PON2
mRNA expression. Phylogenetic analysis
suggests that PON2 is the oldest member
of the family. It is reportedly present in-
tracellularly in three major vascular cell
types, namely cultured human umbilical
veinendothelialcells,smoothmusclevas-
cular cells, and aortic adventitial ﬁbro-
blasts, with the major function of
reducing reactive oxygen species–
mediated endothelial cell dysfunction (22).
In this study, the BRECs were found
to increase PON-HCTLase activity upon
exposure to HCTL. Comparatively, PON-
HCTLase activity was two- to threefold
higher upon exposure to Hcys. The
mRNA expression of PON2 was similarly
increased. Concomitantly, there was a
signiﬁcant drop in the AREase activity
both in the HCTL- and Hcys-treated
BRECs. The differential effect seen in
Hcys- and HCTL-treated cells may be ex-
plained by the differential uptake of the
molecules and characteristics of the cell
type. The retinal capillary endothelial cell
uptake of Hcys and HCTL has not been
examined. However, Hcys transport is
differentially regulated in vascular cells.
Inendothelialcells,Hcystransportispre-
dominantly mediated by a sodium-
lysosome–dependent system ASC with
low transport activity (23). To see if the
binding characteristics of PON with Hcys
alters the PON-HCTLase and AREase ac-
tivity,wetookabioinformaticsapproach.
PON2 bound to two Ca
2
 ions was mod-
eled using MODELER 9V7 (24) on the
basis of the crystal structure of PON1
(1V04) as template, given by Hasel et al.
(25). Because the binding of Hcys to
PON2 protein is not known, blind dock-
ing was done (Fig. 3A and B). The dock-
ing study reveals that Hcys binds to the
samepockettowhichHCTLandPAdock
(Table 2). Therefore, it is quite possible
that Hcys can affect the PON-HCTLase
and PON-AREase activity of PON2.
This is the ﬁrst report showing that
theincreasedactivityofPON-HCTLaseat
the level of vitreous may be a protective
effect to eliminate HCTL, which mediates
endothelial cell dysfunction through N-
homocysteinylation of the lysine residues
intheproteins(26),whilePON-AREaseis
lowered, probably due to the increased
Hcys levels. Vitreous levels of HCTL and
PON activities can be markers of diabetic
retinopathy. However the structure func-
tion that determines the dual-enzyme ac-
tivity of PON, which is altered by
moleculeslikeHcys,suchasinPDR,war-
rants further attention.
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